The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.
Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback